Vital Images reports record quarter
Executives at imaging software pioneer Vital Images are celebrating results from a strong first quarter, ended March 31. The company reported April 22 that revenues grew 53% to $6.8 million in the first fiscal quarter compared with the same period a year
Executives at imaging software pioneer Vital Images are celebrating results from a strong first quarter, ended March 31. The company reported April 22 that revenues grew 53% to $6.8 million in the first fiscal quarter compared with the same period a year ago. Jay D. Miller, company president and CEO, forecast 35% to 45% growth in core revenue components for the rest of 2003 as products meet well-defined clinical needs in the imaging marketplace. For the first quarter, revenue from the company's core components-software license fees and maintenance and services-rose 61% to $6.3 million from $3.9 million for 1Q 2002. Net income was $654,000 versus a net loss of $247,000 in the year-ago period. The company cited revenue from Toshiba, which distributes Vital Images' Vitrea workstation with its multidetector scanners, as having been especially strong, contributing 45% of first quarter revenues. Revenue from Toshiba also accounted for 45% of Vital Images' revenue in the first quarter of last year. Vital Images executives also noted the company had reached a milestone during the quarter: the sale of its 1000th Vitrea.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
New PSMA PET Prep Product Now Available in the U.S.
June 11th 2025Offering an extended shelf life, the FDA-approved Gozellix, a preparation kit for gallium-68 (68Ga) gozetotide injection, is indicated for use in PSMA PET imaging of prostate cancer patients with suspected recurrence or metastasis.
